Precision Medicine for Neurodevelopmental Disorders

STALICLA is a biotech company focused on neurodevelopmental disorders. Its unique mission is to identify, develop and bring precision medicine to patients with neurodevelopmental disorders, with a first application in autism spectrum disorder.

Find out more

Autism Spectrum Disorder statistics

A highly common condition 10 million patients in USA + EU
Lack of clear characteristics 80% of cases are idiopathic
No treatment 0 treatments address core symptoms
High economic burden Cost of ASD was $268 billion in 2015 in USA

Matching patients with personalized treatments

STALICLA’s first precision medicine STP1 aims to serve a sub-group of patients with autism spectrum disorder. STP1 is advancing towards a Phase 1b clinical trial due to start in the US second half of 2020.

Matching patients with personalized treatments

STALICLA's discovery technology for precision medicine

STALICLA has developed a first-in-class neurodevelopmental disorders -focused AI technology disrupting drug discovery and development approaches in the field.

Find out more

Search for content on Stalicla...